OR WAIT null SECS
Eisai has announced an expansion of its manufacturing operations at its Hatfield production plant in the United Kingdom to meet global demand.
Global pharmaceutical company, Eisai, has announced an expansion of its manufacturing operations at its Hatfield production plant in the United Kingdom to meet global demand. The investment was revealed in a Nov. 16, 2020 press release.
The company is investing £11.5 million (US $15.2 million) in two new packaging lines at the Hatfield production plant to triple product output over the next three years. The packaging capabilities will be expanded with blistering and serialization, as well as high containment systems as standard, which will enable the company to offer full-service support for a larger global supply of its products.
“To meet the demand that we have currently as well as the demand that is projected in the future, we need to ensure that our facilities continue to grow and supply vital medicines—even during the current global covid-19 pandemic,” said Alex Felthouse, managing director of Eisai Manufacturing Limited, in the press release. “We have taken extra measures to equip our facilities with the safety precautions needed for our well-trained staff to continue producing and packaging our medicines and will continue to seek out new investment opportunities as part of our five-year growth strategy.”